SCHEMBL1706093

SCHEMBL1706093

CCc1c(Oc2ccc(C)cc2)nc(C)nc1C(C)NS(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.41
S1PR1 P21453 5/20 0.40
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
PGR P06401 1/20 0.38
CCR2 P41597 3/20 0.36
S1PR3 Q99500 1/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
CA12 O43570 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HTR2A P28223 1/20 0.34
SLC6A4 P31645 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12156213 0.88 CYP1A2 (0.38) CNR1S1PR1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL1706092 0.85 S1PR1 (0.38) CNR1S1PR1ALDH1A1S1PR3KMT2A
SCHEMBL12156293 0.81 ALDH1A1 (0.42) CNR1S1PR1ALDH1A1SMN1; SMN2PGR
SCHEMBL2280153 0.80 CNR1 (0.41) CNR1S1PR1ALDH1A1SMN1; SMN2PGR
SCHEMBL12156325 0.74 S1PR1 (0.43) CNR1S1PR1ALDH1A1SMN1; SMN2PGR
SCHEMBL12156327 0.74 CNR1 (0.50) CNR1S1PR1ALDH1A1SMN1; SMN2PGR
SCHEMBL2275395 0.74 S1PR1 (0.49) S1PR1S1PR3CYP2C19
SCHEMBL12160659 0.73 S1PR1 (0.67) CNR1S1PR1S1PR3KMT2ACYP2C19
SCHEMBL12160963 0.73 S1PR1 (0.67) CNR1S1PR1S1PR3KMT2ACYP2C19
SCHEMBL12160958 0.72 S1PR1 (0.57) CNR1S1PR1ALDH1A1PGRS1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2177512-B1 INHIBITOR OF BINDING OF S1P1 TAISHO PHARMACEUTICAL CO LTD (JP) 2012-04-18 EP disclosed
US-8048898-B2 Inhibitor of binding of S1P1 TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-11-01 US disclosed
US-8048898-B2 Inhibitor of binding of S1P1 TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-11-01 US disclosed
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-09-16 US disclosed
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-09-16 US disclosed
EP-2177512-A1 INHIBITOR OF BINDING OF S1P1 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 S1PR1, S1PR3, EDNRB CNR1 24/4885S1PR1 1/4885ALDH1A1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.